SHPCX Fees and Costs — Saratoga Health & Biotechnology Portfolio, Health & Biotechnology Class C
Data updated: 2026-07-24
The net expense ratio is 3.60%. This share class carries a deferred sales charge of up to 1.00%. In fiscal 2025 the fund paid $2K in broker commissions, 0.0187% of average net assets, and portfolio turnover was 22%.
SHPCX Fees and Expenses
Annual operating expenses and sales charges of SHPCX. Prospectus, as of December 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 1.25% |
| 12b-1 fee | — |
| Other expenses | 1.35% |
| Gross expense ratio | 3.60% |
| Fee waiver | — |
| Net expense ratio | 3.60% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 1.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
SHPCX Costs Over Time
On $10,000 invested in SHPCX, assuming 5% a year before costs, total costs come to $2,148 over 5 years, cutting the return by 3.80% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $101 | $0 | $0 |
| Fund expenses (net expense ratio 3.60%) | $378 | $1,148 | $1,936 |
| Trading costs (broker commissions) | $2 | $6 | $10 |
| Lost growth on money paid in costs | $0 | $58 | $202 |
| Total costs | $481 | $1,212 | $2,148 |
| Value after costs | $10,019 | $10,364 | $10,615 |
| Impact on return, per year | 4.81% | 3.80% | 3.80% |
SHPCX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending August 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.0187%
- Total broker commissions: $2K
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 22%
- Securities on loan, average value: $66K
- Net income from securities lending: $105 (0.001% of average net assets)
SHPCX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Instinet, Inc. | $971 | 47.57% |
| Cowen Group | $778 | 38.11% |
| SG Securities | $292 | 14.31% |
Saratoga Health & Biotechnology Portfolio Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| SBHIX | Health & Biotechnology Class I | 2.60% | none |
| SHPAX | Health & Biotechnology Class A | 3.00% | 5.75% |
| SHPCX | Health & Biotechnology Class C | 3.60% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.